Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-244-6 | CAS number: 3040-44-6
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
- Principles of method if other than guideline:
- according to BASF-internal standard
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 2-piperidinoethanol
- EC Number:
- 221-244-6
- EC Name:
- 2-piperidinoethanol
- Cas Number:
- 3040-44-6
- Molecular formula:
- C7H15NO
- IUPAC Name:
- 2-piperidinoethanol
- Details on test material:
- Name of the test substance used in the study report: 1-(2-hydroxyethyl)-piperidin
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- The animals were offered a standardized animal laboratory diet.
Fasting period: 15 - 20 hours before administration.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Concentration used were 4.64, 10, 14.7, 21.5 and 31.6% (G/V).
Application volume (ml/kg): 10 - Doses:
- 464, 1000, 1470, 2150, 3160 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 1 100 mg/kg bw
- Mortality:
- Male animals: 464 mg/kg: no deaths after 14 days; 1000 mg/kg: 2/5 after 14 days; 1470, 2150 and 3160 mg/kg: 5/5 after 14 days
Female animals: 464 and 1000 mg/kg: 1/5 after 14 days; 1470, 2150, 3160 mg/kg: 5/5 after 14 days - Clinical signs:
- other: Dyspnea, gasping, apathy, abnormal position, staggering, atony, trembling, twitching, spastic gait, fibrous twitching, ruffled fur, exsiccosis, exophthalmos, salivation, chromodacryorrhea, agglutinated snouts, constraint gnawing, poor general state.
- Gross pathology:
- Animals that died: acute congestive hyperemia; gastro-intestinal tract: hemorrhagic enteritis, atonic, diarrheic bloody content.
Sacrificed animals: stomach: forefront of the forestomach thickened.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
